Highlights of This Issue 773

REVIEWS

775 Hey Factors at the Crossroad of Tumorigenesis and Clinical Therapeutic Modulation of Hey for Anticancer Treatment
Zihao Liu, Andrew J. Sanders, Gehao Liang, Erwei Song, Wen G. Jiang, and Chang Gong

787 Nodal Signaling as a Developmental Therapeutics Target in Oncology
Aparna Kalyan, Benedito A. Carneiro, Sunandana Chandra, Jason Kaplan, Young Kwang Chae, Maria Matsangou, Mary J.C. Hendrix, and Francis Giles

SMALL MOLECULE THERAPEUTICS

793 Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK–p90RSK–mTOR Signaling Network
Suman Chatterjee, Eric H.-B. Huang, Ian Christie, Brenda F. Kurland, and Timothy F. Burns

805 Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer

819 Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates
Zhanjun Hou, Leda Gattoc, Carrie O’Connor, Si Yang, Adrienne Wallace-Povill, Christina George, Steve Orr, Lisa Polin, Kathlyn White, Juwanna Kushner, Robert T. Morris, Alexey Gargueev, and Larry H. Matherly

831 Fluorinated N,N’-Diarylureas As Novel Therapeutic Agents Against Cancer Stem Cells
Dasha E. Kenlan, Piotr Bychahou, Vitaliy M. Sviripa, Heidi L. Weiss, Chunming Liu, David S. Watt, and B. Mark Evers

LARGE MOLECULE THERAPEUTICS

838 Synthesis and Evaluation of the Novel Prostamide, 15-Deoxy, Δ12,14-Prostamide Jα, as a Selective Antitumor Therapeutic
Daniel A. Ladin, Eman Soliman, Rene Escobedo, Timothy L. Fitzgerald, Li V. Yang, Colin Burns, and Rukiyah Van Dross

850 Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models

861 Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Elena Burova, Aynur Hermann, Janelle Waite, Terra Potocky, Venus Lai, Seongwon Hong, Matt Liu, Omaira Allbritton, Amy Woodruff, Qi Wu, Amanda D’Orrvilliers, Elena Garnova, Ashique Rafique, William Poseymirou, Joel Martin, Tammy Huang, Dimitris Skokos, Joel Kantrowitz, Jon Popke, Markus Molina, Douglas MacDonald, Ella Ioffe, William Olson, Israel Lowy, Andrew Murphy, and Gavin Thurston

871 Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers
879  Highly Potent, Anthracycline-based Antibody–Drug Conjugates Generated by Enzymatic, Site-specific Conjugation
Nikolas Stefan, Rémy Gebéieux, Lorenz Waldmeier, Tamara Hell, Marie Escher, Fabian I. Wolter, Ulf Grawunder, and Roger R. Beerli

893  Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer
Jörg Willuda, Lars Linden, Hans-Georg Lerchen, Charlotte Kopitz, Beatrix Stelte-Ludwig, Carol Pena, Claudia Lange, Sven Golfiger, Christoph Kneip, Patricia E. Carrigan, Kirk Mclean, Kathleen Stuebner, Anthony E. Rizzardi, Jonathan C. Henriksen, Stephen Schmechel, Colleen L. Forster, Jong-Hyuk Kim, Jerry Froelich, Jillian Walz, Michael S. Henson, Matthew Breen, Kerstin Lindblad-Toh, Felix Oh, Kristy Pilbeam, Jamie F. Modiano, and Daniel A. Vallera

905  Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth

914  Inhibition of Isoprenylcysteine Carboxymethyltransferase Induces Cell-Cycle Arrest and Apoptosis through p21 and p21-Regulated BNIP3 Induction in Pancreatic Cancer
Kanjoo J. Manu, Yian Fan, Jing Tsong Teh, Wan Long Zhu, Patrick J. Casey, and Mei Wang

924  Role of STAT3 and FOXO1 in the Divergent Therapeutic Responses of Non-metastatic and Metastatic Bladder Cancer Cells to miR-145
Guosong Jiang, Chao Huang, Jingxia Li, Haishan Huang, Honglei Jin, Junlan Zhu, Xue-Ru Wu, and Chuanshu Huang

936  Calcium-Dependent Enhancement by Extracellular Acidity of the Cytotoxicity of Mitochondrial Inhibitors against Melanoma
Fumihito Noguchi, Shigeki Inui, Clare Fedele, Mark Shackleton, and Satoshi Itami

COMPANION DIAGNOSTICS AND CANCER BIOMARKERS

948  Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology
Hatim Husain, David Nykin, Nam Bui, Daniel Quan, German Gomez, Brian Woodward, Sumathi Venkatapathy, Radha Duttagupta, Eric Fung, Scott M. Lippman, and Razelle Kurzrock

MODELS AND TECHNOLOGIES

956  Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR

966  HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer
Karem A. Court, Hiroto Hatakeyama, Sherry Y. Wu, Mangala S. Lingegowda, Cristian Rodríguez-Aguayo, Gabriel López-Berestein, Lee Ju-Seog, Carlos Rinaldi, Eduardo J. Juan, Anil K. Sood, and Madeline Torres-Lugo

RETRACTION

977  Retraction: Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover shows the whole genome evaluation of copy number alterations ordered sequentially by chromosomes and represented by different colors. A patient with metastatic lung cancer was found to have very high amplification of EGFR (copy number = 15) and HFN1B (copy number = 11) detected by cell-free DNA obtained from ascites. The results indicate that cell-free DNA from ascites and pleural effusions may provide additional data complementing tumor and plasma cell-free DNA molecular characterization, and a context for important insights into clonal dynamic change within primary tumor and metastatic deposits.